Sustainability
Inspired by our purpose to revolutionise care for people and planet, our sustainability roadmap to 2030, WeCare, guides us and lends structure to our sustainability efforts. It is a driver for growth, innovation and productivity and an essential part of our employee value proposition.
Our ambition is to transform our business to become a global leader in sustainable healthcare
Revolutionising care
Following a materiality analysis in 2021, we launched WeCare. Based on the Paris Agreement and the UN Sustainable Development Goals, WeCare embeds social, environmental, and economic value for patients and healthcare providers across our product and service offering. It also directs how we conduct our business in the short- mid- and long-term to create a sustainable, equitable and inclusive future.
-
Mölnlycke reviews a materiality analysis at least every second year to identify which issues to prioritise, manage and monitor to create shared value for society, the environment and the economy, as well as identify future challenges and opportunities for the company. In the 2022 materiality analysis, various stakeholders, including Mölnlycke’s employees, customers, distributors, suppliers, national sector organisations and students helped to identify 20 material aspects that were of primary importance, and prepared the ground for the company’s WeCare roadmap.
The results showed that topics such as decent safe employment, diversity equity and inclusion, waste and circularity, sustainable innovation and development, and community support gained importance compared to the last materiality analysis in 2020. Other material aspects, such as biodiversity and responsible taxation approach, were found to have a lower significance.
In 2023 Mölnlycke started to prepare for the Corporate Sustainability Reporting Directive (CSRD) and Corporate Sustainability Due Diligence Directive (CS3D) implementation by performing a Double Materiality assessment and consequent gap analysis
evaluation.
"Recognising the profound and ongoing pressure on environment, society and global healthcare systems in particular, Mölnlycke are accelerating our transformation to deliver sustainable healthcare solutions. We are uniquely positioned to improve patient lives while reducing the environmental impact of healthcare."
Zlatko Rihter Chief Executive Officer
Ethical business
We set high standards of ethics and responsibility in our business and act with integrity and care for human rights throughout our value chain.
Our commitment to reach Net Zero by 2050
We've formalised our climate change mitigation efforts by publicly committing to the Science Based Targets Initiative (SBTi), and securing their validation of our near-term climate targets, detailed below:
-
Reducing absolute scope 1 and 2 GHG emissions by 50% by 2030 from a 2021 base year.
-
Increasing active annual sourcing of renewable electricity from 23% in 2021 to 100% by the end of 2024 and continuing active annual sourcing of 100% of renewable electricity through 2030.
-
Reducing absolute scope 3 GHG emissions from purchased goods and services (cat. 1), fuel and energy related activity (cat. 3), upstream transportation and distribution (cat. 4) and waste generated in operations (cat. 5) by 20% by 2028 from a 2021 base year.
-
Having 63% of our suppliers by emissions covering purchased goods and services (cat. 1) capital goods (cat. 2), and upstream transportation and distribution (cat. 4) committed to the Science Based Targets Initiative by 2028.
Milestones on the way to Net Zero
2016: Scope 1 and 2 GHG emissions measured and baseline established.
2021: Materiality analysis and development of WeCare (2030 sustainability roadmap).
2021: Upstream and downstream scope 3 GHG emissions measured and baseline established.
2021: First range of BARRIER® surgical drapes launched with demonstrable reductions in emissions.
2022: Commitment to SBTi and nine manufacturing sites operating on 100% fossil-free electricity.
2023: Validation of near-term GHG emission reduction targets by SBTi.
2023: Sustainable Product Portfolio Assessment conduced for Operation Room Solutions and Antiseptics portfolios.
Sustainability news
See all news-
Mölnlycke sets sail with ocean biofuel: A step towards greener logistics
Longstanding partners, Mölnlycke Health Care and Scan Global Logistics (SGL), have entered an agreement for the purchase and deployment of ocean biofuel covering trade lanes from Asia to Europe to further reduce carbon emissions. This decision supports the global MedTech company Mölnlycke's commitment to reducing greenhouse gas (GHG) emissions and reaching Net Zero by 2050. For over 15 years, Scan Global Logistics have had a close global partnership with Mölnlycke, marked by a shared focus on supply chain optimisation and mitigating greenhouse gas (GHG) emissions associated with maritime transportation. In recent years, this collaboration has seen a heightened emphasis on sustainability initiatives, culminating in exploring actions to reduce environmental impact, which resulted in the company now buying ocean biofuel. Eric de Kesel, COO & EVP Sustainability, Mölnlycke, elaborates on this decision: “We are committed to driving our sustainability efforts forward and firmly believe we can reduce emissions while maintaining the quality of our business operations. The partnership with Scan Global Logistics to purchase a significant amount of biofuel for our ocean shipments is important and beneficial from a business, economic, and environmental standpoint, particularly for our Asia-Europe routes.” Striking a balance: Sustainable and economical solutions in logistics Both companies recognise the importance of offering tangible solutions to address climate change-related concerns, anchoring their collaboration in a mutual commitment to push for positive change. Kim Fischer, Corporate EVP, Global Sales & Corporate Strategic Accounts in Scan Global Logistics, reinforces this commitment: “Mölnlycke is very important to us, and our relationship dates back over a decade. This initiative underlines the dynamic and innovative approach that both companies are investing in a successful business collaboration. Further sustainability initiatives have already been discussed with Mölnlycke, and we value such entrepreneurship, which aligns with our business approach.” Marc Bach Spangsberg Sørensen, Global Head of Program Management at Scan Global Logistics, continues: ”We are dedicated to expanding the portfolio of relevant products offered to our customers in an ever-changing world. Through strategic collaborations, we promote the agenda for alternative fuel types, contributing to the long-term transition to low-emisssion transport solutions.” Central to this collaboration is the ability to provide customers like Mölnlycke with accessible, measurable, and ready-for-use products that facilitate GHG emission reduction. By leveraging biofuel for ocean freight, SGL aim to deliver environmental and economic benefits through cost-effective pricing structures. Partnerhips as drivers for positive change Martin Andersen, Global Head of Sustainability & ESG at Scan Global Logistics, is excited about the collective courage among companies which will support the demand for ocean biofuel and actual emission reductions: ”It is paramount and uplifting to see responsible companies drive their decarbonisation journey. It is a challenge, but we all must contribute and support each other with collaboration across industries and supply chains, which is essential to making progress. The window for meaningful change is closing; now is the time to drive collective courage for a low-carbon future.” In conclusion, this partnership for ocean biofuel represents a positive step towards low-carbon logistics. While navigating the complexities of modern logistics, collaborations like these serve as examples of optimism and pave the way towards a more sustainable future for the industry.
-
Mölnlycke integrated Annual Report 2023
Performance highlights Mölnlycke reported strong growth in 2023, with net sales reaching EUR 1,924 million, an 8% increase in constant currency rates. The EBITDA grew by 14% to EUR 545 million, reflecting substantial organic growth and market share gains across most markets. Sustainability achievements We made significant strides in operationalising our sustainability roadmap 2030. Mölnlycke’s near-term greenhouse gas emission reduction targets were validated by the Science Based Targets initiative. Noteworthy progress was made in our journey towards 100% fossil-free electricity by the end of 2024, with 61% fossil-free electricity share in 2023. We also achieved a 20% reduction in overall absolute greenhouse gas emissions across the entire value chain compared to the 2021 baseline. Finally, we expanded the scope of Life Cycle Assessment to cover 30% of our portfolio in terms of net sales. Zlatko annual report news quote Innovation and quality highlights To enhance surgical performance, Mölnlycke introduced hand scanning technology using artificial intelligence and machine learning for optimal glove fit, launched Mepilex® Up in the US, upgraded the Mepilex® Border Post-Op product family globally and registered Hibiwash®, - the new colour- and fragrance-free Hibi formula. We also successfully completed the transition to Medical Device Regulation (MDR), one of the first MedTech companies to do so. Strategic investments Mölnlycke secured long-term financing through a EUR 400 million Eurobond and a EUR 350 million Revolving Credit Facility. We also decided to invest EUR 60 million to increase production capacity, including a new Mepilex Border Flex production line and a new Ethylene Oxide sterilisation unit in Finland.
-
In 2023 Mölnlycke was awarded a gold medal for Sustainability by EcoVadis
The benchmarking procedure Mölnlycke are in the second year of working with EcoVadis as an independent and credible organisation to benchmark strengths and improvement opportunities. The rating process required extensive amounts of data and documentation, and therefore teamwork between global sustainability, legal and compliance, information technology, procurement excellence, and people experience teams. Our submission was assessed over a four week period. As a continuation from the previous assessment, results and feedback will be used to prioritise improvement plans. The result A gold medal is awarded to the all top 5%, and our score puts us into the top 3% of all organisations from all industries worldwide. Particularly recognized during the submission were Mölnlycke's commitment to Science Based Targets and measurable improvements in emissions, the strength of Mölnlycke procedures relating to human rights, demonstrable progress in gender equality, and the availability of the Ethics Hotline to all Mölnlycke's stakeholders The results certificate is available to download for verification below, EcoVadis will also provide a detailed validated scorecard to users of their platform.
-
Mölnlycke to help establish cleft care centre in the Philippines
Being born with a cleft lip or palate is more than just a cosmetic problem. Many children have issues eating or speaking. They can grow up isolated, unable to socialise and deprived of opportunities. The Philippines has one of the highest incidences of cleft palate and cleft lip in the world. A simple surgical procedure can correct cleft problems. But access to healthcare is low in the country, particularly for people living outside the two main islands, and there is a need to enhance the specialist cleft care skills of healthcare professionals. 10,000 surgeries in three years The centre, which is planned to open in Q4 2021, will serve the 27 million people who live on Cebu or one of the 150+ surrounding islands. In its first three years, Operation Smile and Mölnlycke estimate that the centre will support up to 10,000 surgeries, via a hub and spokes model in the community. More than 26,000 patients will receive consultations and 1,800 community health workers will be trained – alongside 400 Operation Smile volunteers and hospital staff. Supporting with funds, products and expertise Mölnlycke has committed to an initial three-year partnership agreement to support the centre at Cebu. In addition to funds, the company will donate products, train healthcare professionals in infection prevention and provide logistics support. As expertise within Cebu and the surrounding area grows, the ambition is for the centre to become less reliant on direct support and more self-sufficient. Zlatko cleft centre Quote Follow #Cebu10000 #Cebu10000 is the first time Mölnlycke has supported healthcare infrastructure and marks a significant step-change in the company’s relationship with its global charity partner Operation Smile. Since 2004, when Mölnlycke began its support of Operation Smile, the company has donated funds, volunteer time and more than 1.5 million pairs of Biogel® surgical gloves to support cleft procedures. A model of cleft care Bill Magee Cleft centre Quote Press contact Liz Neal Director of Communications Email: liz.neal@molnlycke.com Phone: +44 7787432560 About Mölnlycke Mölnlycke Health Care is a world-leading MedTech company that specialises in innovative solutions for wound care and surgical procedures. Mölnlycke products and solutions are used daily by hospitals, health care providers and patients in over 100 countries around the world. Founded in 1849, Mölnlycke is owned by Investor AB and headquartered in Sweden. www.molnlycke.com